Bayer's Missouri Courtroom Test Weighs on Shares as FDA Fast-Tracks Lynkuet

Bayer faces a new Roundup liability trial in Missouri as its stock falls 10% over seven days, while the company reports FDA and patent progress.

A fresh Roundup liability trial opened Tuesday in the US state of Missouri, and the proceedings are being watched as a bellwether for how juries and courts may handle the thousands of remaining claims over the alleged carcinogenic effects of the glyphosate-based weedkiller. Bayer continues to deny the allegations. Reuters reported that the outcome could offer a signal for the direction of future litigation.

The hearing weighed on sentiment in Frankfurt. Bayer shares closed Friday at EUR 45.02, a decline of 10 percent over the past seven days. Media reports pointed to persistent legal and regulatory risks in the United States rather than any single fresh catalyst behind the move, with selling pressure building noticeably during Thursday's session. Despite the recent pullback, the stock is still up 22 percent since the start of the year, having recovered from earlier lows.

Glyphosate litigation has dogged the Leverkusen-based group for years, and each verdict has the potential to reshape estimates of its future financial obligations. Periods of legal uncertainty repeatedly push the valuation back into a more cautious light, even as the broader year-to-date trend remains positive.

Pharma Pipeline Delivers Regulatory Wins

Running alongside the courtroom risk, Bayer reported progress on the drug development front. On Monday the company said the US Food and Drug Administration has accepted Lynkuet for priority review for an additional indication covering vasomotor symptoms in women undergoing endocrine therapy for HR-positive breast cancer. Development projects at subsidiary BlueRock Therapeutics also picked up special designations in both the US and Europe.

Bayer also held its ground on another legal front. A US federal judge rejected motions from Pfizer, BioNTech and Moderna to dismiss mRNA patent suits filed by the company's Monsanto unit, meaning those proceedings will continue through the regular US court process.

On the organizational side, Dr. Christoph Koenen took over as Chief Medical Officer of the pharmaceutical division, adding the role to his existing responsibilities in order to steer the segment's medical strategy. These operational steps drew little reaction from investors, who remain focused on the legal situation.

A $2.2 Billion Bet on American Manufacturing

Longer-term growth is meant to come from an expansion of global production capacity. Bayer announced a USD 2.2 billion investment in a new pharmaceutical manufacturing site in New Albany, Ohio. The company expects roughly 600 permanent positions there, plus another 1,500 temporary construction jobs.

The project reinforces Bayer's pharmaceutical footprint in the key US market and underscores the division's long-term orientation, though it also ties up substantial capital. The build-out follows a phased schedule: active ingredient production is slated to begin in 2031, with finished drug manufacturing planned for 2034.

In Germany, Bayer will take the existing primary clarifier at its Bergkamen wastewater treatment plant out of service starting October 5, with the work expected to take several weeks.

Quarterly Update on the Calendar

Market participants are looking to the next set of results for a clearer read on the operating business. Bayer will publish its quarterly statement for the third quarter of 2026 on November 3, 2026 at 07:30 CET, followed by an investor conference at 14:00 CET.